Guardant Health, Inc. (GH)
NASDAQ: GH · IEX Real-Time Price · USD
30.75
-0.40 (-1.28%)
At close: Jul 19, 2024, 4:00 PM
30.87
+0.12 (0.39%)
Pre-market: Jul 20, 2024, 9:28 AM EDT
Guardant Health Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Guardant Health stock have an average target of 37.17, with a low estimate of 27 and a high estimate of 50. The average target predicts an increase of 20.88% from the current stock price of 30.75.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for GH stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 6 | 6 |
| Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Hold | 2 | 2 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 12 | 12 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $28 → $32 | Strong Buy | Maintains | $28 → $32 | +4.07% | Jul 17, 2024 |
| Guggenheim | Guggenheim | Hold → Strong Buy Upgrades $36 | Hold → Strong Buy | Upgrades | $36 | +17.07% | Jun 28, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $30 → $38 | Strong Buy | Maintains | $30 → $38 | +23.58% | Jun 4, 2024 |
| Jefferies | Jefferies | Strong Buy Initiates $32 | Strong Buy | Initiates | $32 | +4.07% | Jun 3, 2024 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $44 | Buy | Reiterates | $44 | +43.09% | May 24, 2024 |
Financial Forecast
Revenue This Year
701.79M
from 563.95M
Increased by 24.44%
Revenue Next Year
838.19M
from 701.79M
Increased by 19.44%
EPS This Year
-3.23
from -4.28
EPS Next Year
-2.82
from -3.23
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 720.3M | 910.0M | 1.1B | 1.4B | 1.8B |
| Avg | 701.8M | 838.2M | 1.0B | 1.2B | 1.4B |
| Low | 664.4M | 743.0M | 840.8M | 953.5M | 1.1B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 27.7% | 29.7% | 32.7% | 40.6% | 50.1% |
| Avg | 24.4% | 19.4% | 21.7% | 18.1% | 17.0% |
| Low | 17.8% | 5.9% | 0.3% | -6.5% | -9.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.55 | -1.52 | -0.66 | -0.11 | 1.54 |
| Avg | -3.23 | -2.82 | -2.42 | -0.42 | 1.51 |
| Low | -3.58 | -3.34 | -3.65 | -0.71 | 1.44 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.